BioCentury | Jun 28, 2010
Clinical News

TOL101 regulatory update

...in patients ages 16 years or younger with preserved pancreatic beta-cell function. The mAb against alpha beta T cell receptor...
BioCentury | Jan 11, 2010
Emerging Company Profile

Tolera: Delta Force Improves Tolerance

...Corporate Profile Tolera Therapeutics Inc. is developing a mAb against the alpha beta T cell receptor designed to improve upon...
...cytokine release syndrome and new or reactivated infections. Tolera believes TOL101, a mAb against the alpha beta T cell receptor...
...conducted early clinical trials of a predecessor antibody. The results suggested that specifically targeting the alpha beta T cell receptor...
BioCentury | Jan 11, 2010
Emerging Company Profile

Sidebar: Tolera: Delta Force Improves Tolerance

Tolera Therapeutics Inc. Kalamazoo, Mich. Technology: Anti-T cell receptor mAb to treat T cell-mediated diseases Disease focus: Autoimmune, cancer Clinical status: Preclinical Founded: 2007 by John Puisis and Maria Siemionow University collaborators: Cleveland Clinic, University...
BioCentury | Oct 14, 1996
Company News

The Scripps Research Institute other research news

The three-dimensional structure of the most common type of T cell receptor was published in Science. The orientation of the receptor as it binds the class I major histocompatibility complex (MHC) molecule also was determined....
Items per page:
1 - 4 of 4